Physician profile
Carl Jenson
NPI 1659317097
$1,925.92
in general payments reported to CMS, 2019-2025
34 companies · $149 in 2025
The $149 reported for 2025 was less than what a typical Radiation Oncology provider received nationally (typical 2025 total: $172).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $256 · 2020: $53.77 · 2021: $90.63 · 2022: $325 · 2023: $581 · 2024: $470 · 2025: $149.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,100 · Education: $99.99.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,100.18 |
| Education | $99.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boston Scientific Corporation | $159.45 | 2019-2021 | |
| Novartis Pharmaceuticals Corporation | $143.61 | 2019-2024 | |
| Amgen INC. | $140.97 | 2022-2023 | Xgeva, Vectibix, Nplate |
| Takeda Pharmaceuticals U.S.A., INC. | $130.89 | 2023-2024 | Iclusig |
| Teleflex LLC | $125.31 | 2025 | Barrigel |
| Mirati Therapeutics, INC. | $124.80 | 2023 | Krazati |
| Gilead Sciences, INC. | $120.00 | 2022 | |
| E.R. Squibb & Sons, L.L.C. | $102.43 | 2023-2024 | Opdualag, Opdivo |
| Sumitomo Pharma America, INC. | $79.47 | 2023-2024 | Orgovyx |
| Daiichi Sankyo INC. | $58.02 | 2019-2024 | Enhertu |
| Novocure INC. | $53.62 | 2022-2025 | Optune Gio |
| Bayer Healthcare Pharmaceuticals INC. | $52.15 | 2020-2024 | |
| Astrazeneca Pharmaceuticals LP | $50.02 | 2024 | Enhertu |
| Merck Sharp & Dohme LLC | $48.54 | 2023-2024 | Keytruda |
| Abbvie INC. | $42.80 | 2019-2022 |
Show all 34 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ipsen Biopharmaceuticals, INC | $42.36 | 2019-2024 | Onivyde |
| Glaxosmithkline, LLC. | $41.05 | 2023 | Jemperli, Zejula, Ojjaara |
| Incyte Corporation | $37.68 | 2020-2024 | Jakafi |
| Seagen INC. | $36.25 | 2019-2023 | Padcev |
| Stemline Therapeutics INC. | $33.60 | 2023 | Orserdu |
| Sobi, INC | $33.22 | 2024 | |
| Regeneron Healthcare Solutions, INC. | $30.50 | 2023 | Libtayo |
| Adc Therapeutics America, INC. | $26.92 | 2024 | |
| Janssen Biotech, INC. | $26.58 | 2024 | Talvey, Tecvayli, Darzalex |
| Celgene Corporation | $25.52 | 2023 | Reblozyl |
| Tersera Therapeutics LLC | $24.58 | 2023 | Zoladex |
| Siemens Medical Solutions USA, INC. | $24.14 | 2023 | Aria Radiation Therapy Management Software, Eclipse Treatment Planning System For External Beam Radiation Therapy |
| Astellas Pharma US INC | $18.01 | 2022 | |
| Myriad Genetic Laboratories, INC. | $17.35 | 2021 | |
| Foundation Medicine, INC. | $16.96 | 2023 | |
| Genzyme Corporation | $15.52 | 2019 | |
| Genentech USA, INC. | $15.26 | 2019 | |
| Pharmaessentia USA Corporation | $15.18 | 2023 | Besremi |
| Eisai INC. | $13.16 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Carl Jenson listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.